Medical Condition News

RSS

CORDIS reports positive results from 10-year follow-up of CYPHER Sirolimus-eluting coronary stent study

Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today at European Society of Cardiology in Stockholm that the results of follow-up tests undertaken ten years after the first patient was treated with a CYPHER(R) Sirolimus-eluting coronary stent have proven outstanding long-term efficacy and safety and were published earlier this year in "JACC: Cardiovascular Interventions".

31 Aug 2010

New book explores history, benefits of tomato

A new history of the tomato in Italy by a University of Leicester historian throws some surprising insights on an item of food that we have been accustomed to think of as intrinsically Italian.

31 Aug 2010

Nutritional recommendations for management of sarcopenia published

Nutritional recommendations for the management of sarcopenia -- also described as age-related muscle and functional loss -- were published this past week in the clinical publication, Journal of American Medical Directors Association.

31 Aug 2010

Outpatient prevention programme by nurses reduces risk of recurrent complications in heart patients

A six-month outpatient prevention programme conducted by nurses has resulted in significant and sustained improvements in the control of cardiovascular risk factors, including high cholesterol or high blood pressure, in patients hospitalised for a heart attack or impending heart attack.

31 Aug 2010

ECG-based screening for young footballers at risk of heart disease needs to be reviewed: Study

The screening process for young footballers at risk of heart disease needs to be re-evaluated. That is the conclusion of a recent study, which has shown that the common criteria used for assessment does not take into account the type and intensity of the exercise performed. The single most common cause of sudden death in competitive footballers is hypertrophic cardiomyopathy - a disease that thickens the heart muscle without any obvious cause.

31 Aug 2010

Older adults likely to have destination memory failures

Older adults are more likely to have destination memory failures - forgetting who they've shared or not shared information with, according to a new study led by Baycrest's Rotman Research Institute.

31 Aug 2010

NewYork-Presbyterian /Columbia sets up new Myelodysplastic Syndromes Center

NewYork-Presbyterian Hospital/Columbia University Medical Center has established a new center devoted to research and treatment of pre-leukemia blood disorders. Known as the Myelodysplastic Syndromes Center, it is one of the largest programs of its kind in the nation.

31 Aug 2010

International Symposium to explore Hybrid approach for congenital heart disease

Interventional cardiologists and cardiothoracic surgeons throughout the United States and the world, who treat patients with congenital heart disease, will gather at the Hilton Columbus at Easton Town Center August 31-September 2, 2010 for the International Symposium on the Hybrid Approach to Congenital Heart Disease (ISHAC).

31 Aug 2010

Study determines dose-specific patterns associated with generic statin switching

Research conducted in the Netherlands has highlighted the need for care when switching patients under treatment for high cholesterol from branded to generic drug families. The study shows that much of the switching can result in patients inadvertently receiving non-equivalent doses, potentially leading to an increased risk of downstream heart disease and stroke.

31 Aug 2010

Veterans with PTSD at greater risk for dementia

Results of a study reported in the September issue of the Journal of the American Geriatrics Society suggest that Veterans with post-traumatic stress disorder (PTSD) have a greater risk for dementia than Veterans without PTSD, even those who suffered traumatic injuries during combat.

31 Aug 2010

Phase 3 AVERROES trial reveals apixaban effective for atrial fibrillation patients unsuitable for warfarin

The phase 3 AVERROES (Apixaban Versus Acetylsalicylic acid (ASA) to Prevent Strokes) trial, designed to show the superiority of apixaban over aspirin for the prevention of stroke or systemic embolism in high-risk atrial fibrillation patients unsuitable for treatment with a vitamin K antagonist (warfarin), was terminated early following a recommendation from the Data Monitoring Committee.

31 Aug 2010

Social interaction reduces physical damage to brain by heart attack: Research

A new study in mice shows how social support can help minimize some of the worst physical damages to the brain caused by a heart attack.

31 Aug 2010

Get With The Guidelines can improve quality of stroke care

The American Heart Association/American Stroke Association’s Get With The Guidelines®–Stroke successfully measured the quality of stroke prevention and care in a nationwide stroke registry in Taiwan and identified important areas for improvement.

31 Aug 2010

Neurobiological markers of depression can help tailor antidepressant treatment to the brain

Depression is actually defined by specific clinical symptoms such as sadness, difficulty to experience pleasure, sleep problems etc., present for at least two weeks, with impairment of psychosocial functioning. These symptoms guide the physician to make a diagnosis and to select antidepressant treatment such as drugs or psychotherapy.

31 Aug 2010

Final regulation to aid Veterans exposed to herbicides published in 'Federal Register'

Veterans exposed to herbicides while serving in Vietnam and other areas will have an easier path to access quality health care and qualify for disability compensation under a final regulation that will be published on August 31, 2010 in the Federal Register by the Department of Veterans Affairs (VA). The new rule expands the list of health problems VA will presume to be related to Agent Orange and other herbicide exposures to add two new conditions and expand one existing category of conditions.

31 Aug 2010

ANTIPAF trial reveals ARBs do not reduce number of AF episodes in paroxysmal AF patients

Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting about 7 million people in Europe. It is a progressive chronic disease in which episodes become more frequent and long-lasting over time. Conventional anti-arrhythmic therapy aims at halting progression and reducing symptoms, but the use of most anti-arrhythmic drugs is compromised by severe side effects, such as pro-arrhythmia or extra-cardiac organ toxicity.

31 Aug 2010

Data monitoring committee recommends early termination following impressive results of AVERROES study

The data monitoring committee of the AVERROES study, seeing overwhelming evidence of the success of apixaban in the prevention of stroke in patients with atrial fibrillation who are unsuitable for the conventional treatment of warfarin, has recommended early termination of this study. The decision came after repeated review and careful consideration of all efficacy and safety data.

31 Aug 2010

Running continuously over 50 or 100 miles may not be good for the heart: Study

In 2009, a study was conducted in UK by Liverpool John Moores University and the Countess of Chester Hospital to assess the effects of running in ultra-endurance races. Typically aimed at super-fit and experienced athletes, these races are held over distances exceeding 50 miles (80 kilometres). The conclusions suggest that some damage is likely to occur to the heart muscle of competitors, while 12 percent of the study group showed signs of significant cardiac damage.

31 Aug 2010

Advanced Life Sciences scientific publication demonstrates triterpenoids' potential as anticancer agents

Advanced Life Sciences Holdings, Inc.,a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced the publication of a research paper in the journal Bioorganic and Medicinal Chemistry Letters that reports data using the Company's core triterpenoid platform technology in the discovery and development of new cancer therapeutic agents.

31 Aug 2010

Telmisartan and amlodipine combination therapy helps achieve high BP control/response rates

Data show that treatment with a single-pill combination of telmisartan, an angiotensin receptor blocker, (ARB) and amlodipine, a calcium channel blocker (CCB) results in significant reductions in blood pressure (BP) in patients with severe hypertension.

31 Aug 2010

Medical Condition News

CORDIS reports positive results from 10-year follow-up of CYPHER Sirolimus-eluting coronary stent study

New book explores history, benefits of tomato

Nutritional recommendations for management of sarcopenia published

Outpatient prevention programme by nurses reduces risk of recurrent complications in heart patients

ECG-based screening for young footballers at risk of heart disease needs to be reviewed: Study

Older adults likely to have destination memory failures

NewYork-Presbyterian /Columbia sets up new Myelodysplastic Syndromes Center

International Symposium to explore Hybrid approach for congenital heart disease

Study determines dose-specific patterns associated with generic statin switching

Veterans with PTSD at greater risk for dementia

Phase 3 AVERROES trial reveals apixaban effective for atrial fibrillation patients unsuitable for warfarin

Social interaction reduces physical damage to brain by heart attack: Research

Get With The Guidelines can improve quality of stroke care

Neurobiological markers of depression can help tailor antidepressant treatment to the brain

Final regulation to aid Veterans exposed to herbicides published in 'Federal Register'

ANTIPAF trial reveals ARBs do not reduce number of AF episodes in paroxysmal AF patients

Data monitoring committee recommends early termination following impressive results of AVERROES study

Running continuously over 50 or 100 miles may not be good for the heart: Study

Advanced Life Sciences scientific publication demonstrates triterpenoids' potential as anticancer agents

Telmisartan and amlodipine combination therapy helps achieve high BP control/response rates

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Latest News